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Abstract
We assessed laboratory monitoring following combination antiretroviral therapy (cART) initiation
among 3,678 patients in a large US multi-site clinical cohort, censoring participants at last clinic
visit, cART change, or three years. Median days (interquartile range) to first hematologic, hepatic,
renal and lipid tests were 30 (18–53), 31 (19–56), 33 (20–59) and 350 (96–1106), respectively. At
one year, approximately 80% received more than two hematologic, hepatic, and renal tests
consistent with guidelines. However, only 40% received one or more lipid tests. Monitoring was
more frequent in specific subgroups, likely reflecting better clinic attendance or clinician
perception of higher susceptibility to toxicities.
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Introduction
Combination antiretroviral therapy (cART) is associated with adverse effects of variable
severity. Adverse effects are among the most common reasons for antiretroviral agent
changes and may be associated with end-organ damage and higher mortality1–3. While
symptomatic effects prompt clinical intervention, asymptomatic adverse effects may go
undetected and result in cumulative toxicity. Laboratory monitoring during cART is
endorsed in developed countries4,5, but guidelines are flexible for resource-limited settings6
due in part to data suggesting that cART can be delivered safely without routine laboratory
monitoring7.
The United States Department of Health and Human Services (DHHS) recommends
laboratory monitoring throughout the course of cART4. This includes serum alanine
transaminase (ALT), aspartate transaminase (AST), total bilirubin, creatinine, and complete
blood count 2–8 weeks after initiating or modifying cART. A repeat of these tests is
recommended every 3–6 months thereafter. Fasting lipid profile is recommended at least
annually4.
Actual laboratory monitoring practices during cART in routine clinical care in the U.S are
unknown. This information is critical to evaluate resource utilization and assess adherence to
guidelines. We evaluated laboratory monitoring among patients who initiated their first
cART regimen between 2000–2010 in a multi-site US clinical cohort.
Methods
This observational clinical cohort included antiretroviral-naïve patients participating in the
Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) who initiated a
first modern cART regimen between 2000–2010 and had at least one laboratory test of any
type after cART initiation. We defined modern cART as a regimen containing a ritonavir-
boosted protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or
integrase inhibitor plus ≥2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTI).
Patients were excluded if their regimen included stavudine, didanosine or unboosted-PIs, or
if they had an abnormal value for the laboratory test being investigated before cART
initiation. CNICS is a collaboration of eight US HIV clinical cohorts8. Ethical approval was
obtained for CNICS from each site’s Institutional Review Board.
We analyzed hematologic, hepatic, renal, and lipid indices following cART initiation.
Hematologic measures included hemoglobin, absolute neutrophil count or platelet count.
Hepatic measures included ALT or AST. We assessed creatinine and non-HDL cholesterol
(calculated by subtracting HDL from total cholesterol) for renal and lipid assessments,
respectively. Abnormal values were defined as: hematologic= hemoglobin≤10 g/dL,
neutrophil count≤750 cells/mm3, or platelet count≤50×109/L; hepatic= ALT or AST≥3
times the upper limit of normal; renal= estimated glomerular filtration rate<50mL/min/
1.73m2; and lipid= non-HDL cholesterol≥160 mg/dL. All analyses were stratified by
laboratory category.
Patients contributed time from cART initiation to the first of: switch/discontinuation of any
antiretroviral for >14 days, loss-to-follow-up (>12 months without a clinic visit), last clinic
visit before Dec. 31, 2010, or 3 years post-cART initiation because <15% of patients
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remained. Post-cART initiation, if an abnormality occurred for the laboratory category being
assessed, patient-time was censored immediately after the abnormality (e.g., patient with
hepatic abnormality was censored when assessing hepatic monitoring but not other
laboratory indices). The initial abnormal test was counted as an event.
We calculated median time-to-first-test, and the cumulative number of tests through 3, 6, 12,
18, and 24 months of cART use. Poisson regression was used to estimate overall testing
rates and rates by time interval following cART initiation. Bivariable and multivariable Cox
regression was used to estimate hazard ratios and 95% confidence intervals in order to
evaluate demographic and clinical characteristics at cART initiation as predictors of time-to-
first-laboratory-test. Repeated events analyses were conducted to evaluate predictors of
time-to-laboratory-test incorporating all tests an individual had during follow-up, using the
Anderson-Gill model and a robust covariance estimator9. Multivariable models included
study site and all variables predictive in bivariable analysis (P<0.10). All analyses were
conducted in SAS10.
Results
Between 2000–2010, 3678 patients started their initial cART regimen and had available
follow-up laboratory data. We excluded patients (N) with hematologic (91), hepatic (98),
renal (129), and lipid (200) abnormalities pre-cART from each respective analysis. No
patients were excluded from all analyses as no patient had all four abnormalities. Overall,
82% were male, 43% white, 37% Black, 15% Hispanic, and 5% other race; 47% were men
who have sex with men; and 8% reported injection drug use. At cART initiation, median age
was 39 years (interquartile range [IQR]:32–45), median year was 2006 (IQR:2004–2008),
median CD4 cell count was 204 cells/mm3 (IQR:64–315) and the median HIV RNA level
was 4.90 log10 copies/ml (IQR:4.41–5.39). Five percent were hepatitis B co-infected and
15% were hepatitis C co-infected. Initial cART regimens were predominantly NNRTI-based
(63%), of which 93% included efavirenz. Additionally, 37% were boosted-PI-based; of
these 56% included atazanavir and 35% lopinavir/ritonavir. Less than 1% of regimens were
integrase-inhibitor-based. Most common NRTIs were emitricitabine/lamivudine (100%),
tenofovir (72%), zidovudine (22%), and abacavir (10%).
A switch or discontinuation of an antiretroviral drug led to censoring of 39% of patients
(N=1434), with a median time to switch/discontinuation of 8.1 months (IQR:3.0–20.2).
Additionally, 26% of patients were lost-to-follow-up, and 21% were censored on December
31, 2010. By 3 years post-cART initiation, 14% of patients (N=515) remained in the study.
Overall, median follow-up time was 11.1 months (IQR:3.8–24.1) with total follow-up of
5112 person-years. For hematologic, hepatic, renal, and lipid analyses, 451, 338, 114, and
553 patients, respectively, were censored earlier because of an abnormal test.
Median days (IQR) to first laboratory test were 30 (18–53), 31 (19–56), 33 (20–59) and 350
(96–1106) for hematologic, hepatic, renal and lipid, respectively. In the first 3 months of
cART, most patients received ≥1 hematologic, hepatic and renal laboratory measure (79%,
78%, and 76%, respectively) and very few a lipid test (16%) (Figure 1). Among patients still
in follow-up one year post-cART initiation, 81%, 79%, and 78% had obtained tests on ≥2
occasions for hematologic, hepatic, and renal, respectively, while 40% received ≥1 lipid test.
Among patients in follow-up for two years, 51% received ≥1 lipid tests.
Monitoring for hematologic, hepatic, and renal tests was highest in the first 6 months of
cART (p<0.001) and plateaued at a lower rate thereafter. Testing rates during the first 6
months of cART were 1.46, 1.42, and 1.37 per 100 person-days for hematologic, hepatic,
and renal, respectively. The corresponding rates between months 6 and 36 of cART were
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0.97, 0.93, and 0.92 per 100 person-days. In contrast, lipid monitoring was consistent across
time from cART initiation and less frequent than other tests at 0.30 per 100 person-days.
We assessed predictors of the rate of first testing and the rate of testing across follow-up
time, stratified by laboratory category (Table 1). More recent calendar years of cART
initiation were associated with shorter times to first lipid test as well as greater lipid
monitoring rates during follow-up. Conversely, the frequency of hematologic, hepatic, and
renal testing appeared stable throughout calendar time. Lower CD4 count and AIDS
diagnosis prior to cART were consistently associated with shorter time to all laboratory tests
and higher monitoring rates across time for all tests except lipids. For hematologic, hepatic,
and renal tests, older age also predicted higher rates of first testing and testing across time.
Hepatitis C co-infection was predictive of higher rates for repeated hematologic tests, but
was not predictive for other monitoring.
Abacavir use was associated with shorter time to first testing and increased monitoring rates
across follow-up for all laboratory types. For hematologic, hepatic, and renal monitoring,
patients on boosted-PI regimens had shorter times to first testing and higher monitoring rates
during follow-up compared to patients with NNRTI-based regimens. Tenofovir use was
associated with shorter time to first hepatic and renal tests, but did not appear predictive of
monitoring rates for repeated tests across time.
Hyperglycemia (diabetes mellitus diagnosis or blood glucose measure >120mg/dL prior to
cART) was predictive of shorter time to first hepatic, renal, and lipid testing, but was only
significantly associated with higher renal monitoring rates across follow-up. Hypertension
(diagnosis or blood pressure >140/90 on at least 2 occasions >1 month apart prior to cART)
was associated with shorter time to first lipid test, but was not predictive of lipid monitoring
rates thereafter. Conversely, while hypertension was not significantly associated with time to
first hematologic, hepatic, or renal tests, it was predictive of overall higher monitoring rates
for these tests across time.
Discussion
In this clinical HIV cohort, routine laboratory monitoring was as frequent as recommended
for hematologic, hepatic, and renal tests for the majority of patients initiating cART between
2000–2010, but lipid monitoring was substantially less than recommended4. Specific clinical
characteristics predicted the relative frequency of testing. This study evaluated a national
multi-site population of HIV-infected patients initiating modern cART in routine clinical
care, allowing our findings to be broadly generalizable in the U.S.
Over 75% of patients received the minimum number of recommended tests for hematologic,
hepatic, and renal abnormalities by one year of cART. More than 30% received more tests
than recommended by one year. Because we only excluded patients based on prior
abnormalities for each laboratory type, these extra tests were likely driven by preceding
diagnoses, co-administration of other medications, symptoms, or abnormalities on other
laboratory tests. In contrast, most patients did not have an annual lipid evaluation, and only
20% of performed tests occurred in the recommended fasting state. In fact, less than half of
patients received a lipid test within the first year, and among patients followed for two years,
only 51% received a lipid test. This is similar to results from a previous study within
CNICS, where 59% of patients had at least one non-HDL measurement during a mean 1.7
years of antiretroviral therapy11. As other monitoring tests were obtained more frequently, it
is unlikely that poor lipid monitoring was driven by poor visit attendance. An alternative
explanation is that clinicians were hesitant to perform lipid testing in patients who were not
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fasting. Monitoring for lipid abnormalities appeared to improve in more recent years, but it
remains substandard.
We observed patterns suggesting that clinicians were selective in the abnormalities
monitored among patient subgroups. Specifically, hematologic, hepatic, and renal tests were
obtained more frequently in those with older age, more advanced HIV disease,
comorbidities, or boosted-PI use. As these tests are often obtained together, it is unsurprising
that a predictor for receiving one type of test may lead to more frequent testing for all three
laboratory categories. While these predictive characteristics may represent patients with
better clinic attendance12,13, these observations likely reflect increased clinician vigilance in
subgroups perceived to have higher susceptibility to toxicities14–16. Consistent with this,
lipids were monitored more frequently in patients with hypertension and hyperglycemia.
Similarly, the association of abacavir use with lipid and renal monitoring may reflect both
the tendency to channel patients with possible renal risk to abacavir, and concerns that
abacavir increases cardiovascular risk, though this is controversial17.
Study limitations include the assessment of monitoring rates only among patients on their
first cART without prior abnormal laboratory values; therefore findings are not
generalizable to patients on subsequent cART regimens or patients with documented
laboratory abnormalities. This approach also resulted in a high-rate of censoring, reflective
of regimen changes and laboratory abnormalities in routine clinical practice18–20. While
current DHHS guidelines specifically recommend fasting lipid panel4, we considered both
fasting and random non-HDL measurements in our analysis. Restriction to the
recommended fasting lipids would have resulted in substantially lower estimates of
compliance with lipid monitoring. While our estimates may underestimate all lipid
monitoring, isolated total cholesterol values provide incomplete screening for lipid
abnormalities, particularly among HIV patients who often do not exhibit classic
dyslipidemic patterns. Also, patients may have obtained tests outside of the CNICS clinics,
potentially leading to underestimates of monitoring rates, though this is unlikely to explain
the discrepancy between monitoring of lipids and other standard labs.
In conclusion, most patients received frequent monitoring in accordance with current
guidelines4 for hematologic, hepatic, and renal abnormalities, but not lipid abnormalities.
Clinicians may be tailoring laboratory monitoring based on perceived risks, and therefore
further assessments of adverse events among patients initiating cART in routine clinical care
are needed. Future research should also focus on optimizing laboratory monitoring strategies
in resource-rich settings, recognizing that research in resource-poor settings has challenged
the benefit and cost-effectiveness of asymptomatic laboratory screening in all patient
populations7,21.
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Cumulative number of tests by laboratory category across time since combination
antiretroviral therapy (cART) initiation, CFAR Network of Integrated Clinical Systems,
between 2000 and 2010. *
*Bold horizontal lines represent range for expected number of laboratory tests based on
2010 DHHS guidelines at 1 year and at 2 years. These ranges were calculated by taking the
recommended frequency of testing and calculating the minimum and maximum number of
tests recommended during the time interval. For example, the minimum for hematologic,
hepatic, and renal tests at one year was calculated as one test for 8 weeks post-cART
initiation and one test 6 months later for a total for a total of 2 tests. Similarly, the maximum
was calculated as one test 2 weeks post-cART and then one test for each 3 month interval
thereafter, totaling 4 tests within the first year.
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Table 1
Independent predictors of laboratory monitoring following combination antiretroviral therapy initiation by
laboratory category, CFAR Network of Integrated Clinical Systems, between 2000 and 2010.
First Laboratory Test* Repeated Tests*
HR (95% CI) HR (95% CI)
Hematologic Tests
Age (by decade increase) 1.06 (1.03, 1.10) 1.03 (1.00, 1.05)
Female Sex - 1.02 (0.95, 1.09)
MSM - 1.01 (0.96, 1.06)
IDU 0.73 (0.64, 0.84) -
CD4 count (by 100 cells/mm3 increase) 0.94 (0.92, 0.97) 0.99 (0.97, 1.01)
Viral load (by log10 increase) 1.01 (0.96, 1.07) 1.00 (0.96, 1.03)
AIDS Diagnosis 1.28 (1.18, 1.39) 1.24 (1.16, 1.31)
cART start year 1.00 (0.99, 1.02) 1.00 (0.99, 1.02)
Boosted-PI (compared to NNRTI) 1.18 (1.10, 1.26) 1.12 (1.07, 1.17)
Zidovudine Use - 1.10 (0.97, 1.25)
Tenofovir Use 1.01 (0.91, 1.13) 1.05 (0.93, 1.19)
Abacavir Use 1.32 (1.16, 1.51) 1.27 (1.14, 1.42)
Hepatitis C - 1.13 (1.05, 1.22)
Hypertension - 1.11 (1.01, 1.21)
Hyperglycemia 1.13 (0.99, 1.30) 1.04 (0.99, 1.10)
Hepatic Tests
Age (by decade increase) 1.07 (1.03, 1.11) 1.04 (1.01, 1.06)
Female Sex - 1.07 (0.99, 1.15)
Race/Ethnicity
 White Ref. Ref.
 Black 0.92 (0.85, 1.00) 0.93 (0.88, 0.98)
 Other 1.06 (0.97, 1.16) 1.05 (0.98, 1.13)
MSM 1.12 (1.04, 1.21) 1.02 (0.97, 1.07)
IDU 0.85 (0.73, 0.98) -
CD4 count (by 100 cells/mm3 increase) 0.95 (0.92, 0.97) 0.97 (0.96, 0.98)
Viral load (by log10 increase) 0.97 (0.92, 1.02) 0.99 (0.95, 1.02)
AIDS Diagnosis 1.33 (1.22, 1.44) 1.22 (1.15, 1.30)
cART start year - 1.01 (1.00, 1.02)
Boosted-PI (compared to NNRTI) 1.23 (1.14, 1.32) 1.15 (1.10, 1.21)
Zidovudine Use 1.16 (0.94, 1.43) -
Tenofovir Use 1.38 (1.10, 1.71) 1.00 (0.93, 1.08)
Abacavir Use 1.53 (1.28, 1.82) 1.26 (1.16, 1.37)
Hepatitis B 1.10 (0.95, 1.29) -
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First Laboratory Test* Repeated Tests*
HR (95% CI) HR (95% CI)
Hepatitis C 0.95 (0.85, 1.05) 1.02 (0.93, 1.12)
Hypertension - 1.09 (1.00, 1.18)
Hyperglycemia 1.19 (1.03, 1.36) 1.03 (0.98, 1.09)
Renal Tests
Age (by decade increase) 1.06 (1.03, 1.10) 1.04 (1.01, 1.07)
Female Sex - 1.02 (0.92, 1.13)
Race
 White Ref.
 Black - 0.95 (0.88, 1.03)
 Other - 1.07 (0.97, 1.18)
MSM - 0.96 (0.89, 1.04)
IDU 0.77 (0.67, 0.88) -
CD4 count (by 100 cells/mm3 increase) 0.95 (0.93, 0.97) 0.95 (0.93, 0.97)
Viral load (by log10 increase) 0.98 (0.93, 1.03) 0.96 (0.91, 1.01)
AIDS Diagnosis 1.29 (1.19, 1.40) 1.37 (1.27, 1.49)
cART start year 1.01 (1.00, 1.03) 1.01 (1.00, 1.03)
Boosted-PI (compared to NNRTI) 1.13 (1.05, 1.22) 1.14 (1.06, 1.22)
Zidovudine Use 1.14 (0.92, 1.42) -
Tenofovir Use 1.41 (1.13, 1.75) 1.01 (0.91, 1.13)
Abacavir Use 1.58 (1.32, 1.89) 1.21 (1.07, 1.36)
Hepatitis C - 1.03 (0.93, 1.14)
Hypertension 1.06 (0.97, 1.15) 1.08 (1.01, 1.16)
Hyperglycemia 1.21 (1.05, 1.39) 1.20 (1.04, 1.39)
Lipid Tests
Age (by decade increase) 1.02 (0.97, 1.07) 1.02 (0.98, 1.06)
Race/Ethnicity
 White Ref. Ref.
 Black 1.09 (0.98, 1.21) 0.90 (0.82, 0.99)
 Other 0.88 (0.77, 1.01) 0.92 (0.83, 1.03)
IDU - 1.01 (0.84, 1.21)
CD4 count (per 100 cells/mm3 increase) 0.95 (0.93, 0.98) -
AIDS Diagnosis 1.14 (1.02, 1.28) -
cART start year 1.06 (1.04, 1.09) 1.02 (1.00, 1.05)
Zidovudine Use 1.09 (0.93, 1.28) -
Tenofovir Use - 1.07 (0.94, 1.23)
Abacavir Use 1.21 (1.03, 1.43) 1.52 (1.30, 1.77)
Hepatitis C - 0.94 (0.83, 1.07)
Hypertension 1.14 (1.02, 1.29) -
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First Laboratory Test* Repeated Tests*
HR (95% CI) HR (95% CI)
Hyperglycemia 1.22(1.00, 1.47) 1.11 (0.96, 1.27)
*
multivariable regression includes all variables predictive in bivariable analysis (all variables with results in column) as well as study site.
HR=hazard ratio; MSM=men who have sex with men; IDU=injection drug user; cART=combination antiretroviral therapy; PI=protease inhibitor;
NNRTI=non-nucleoside reverse transcriptase inhibitor
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